Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

9 Sept 2019

Abstract excerpt

The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor. GB affects 3.2 in 100,000 people who have an average survival time of around 14 months after presentation. Several key aspects make GB a difficult to treat disease, primarily including the high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31505812
DOI: 10.3390/biomedicines7030069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Temozolomide and Other Alkylating Agents in Glioblastoma TherapyPMID 31505812Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69Semantic proximity Read ↗

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read ↗

DNA repair mechanisms and their clinical impact in glioblastomaSemantic proximity Read ↗

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future DirectionsSemantic proximity Read ↗

Chemotherapeutic Drugs: DNA Damage and Repair in GlioblastomaSemantic proximity Read ↗

Obstacles to Glioblastoma Treatment Two Decades after TemozolomideSemantic proximity Read ↗

Temozolomide: Mechanisms of Action, Repair and ResistanceSemantic proximity Read ↗

Novel chemotherapeutic agents for the treatment of glioblastoma multiformeSemantic proximity Read ↗

Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomideSemantic proximity Read ↗

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.